Erythropoietin improves cardiac wasting and outcomes in a rat model of liver cancer cachexia.

[1]  F. López‐Soriano,et al.  Nonmuscle Tissues Contribution to Cancer Cachexia , 2015, Mediators of inflammation.

[2]  S. Anker,et al.  Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. , 2014, Journal of the American College of Cardiology.

[3]  S. Anker,et al.  Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. , 2014, European heart journal.

[4]  V. Baracos,et al.  Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist , 2014, Journal of cachexia, sarcopenia and muscle.

[5]  F. López‐Soriano,et al.  Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models , 2013, Journal of Lipid Research.

[6]  W. Evans,et al.  Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D3-creatine dilution method , 2013, Journal of cachexia, sarcopenia and muscle.

[7]  S. Anker,et al.  Ursodeoxycholic acid treatment in a rat model of cancer cachexia , 2011, Journal of cachexia, sarcopenia and muscle.

[8]  E. Barrey,et al.  Skeletal muscle alterations and exercise performance decrease in erythropoietin-deficient mice: a comparative study , 2012, BMC Medical Genomics.

[9]  F. López‐Soriano,et al.  Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity. , 2011, Experimental and therapeutic medicine.

[10]  D. Lacey,et al.  Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival , 2010, Cell.

[11]  F. Berger,et al.  Activity level, apoptosis, and development of cachexia in Apc(Min/+) mice. , 2010, Journal of applied physiology.

[12]  S. Anker,et al.  No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure. , 2009, International journal of cardiology.

[13]  M. Aapro,et al.  Update on erythropoiesis-stimulating agents and clinical trials in oncology. , 2009, The oncologist.

[14]  A. Cerami,et al.  Erythropoietin‐mediated tissue protection: reducing collateral damage from the primary injury response , 2008, Journal of internal medicine.

[15]  G. Takemura,et al.  Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. , 2006, Cardiovascular research.

[16]  Kenta Ito,et al.  Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. , 2006, Cardiovascular research.

[17]  A. Cerami,et al.  Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. , 2006, Kidney international.

[18]  L. Annemans,et al.  European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment. , 2006, Cancer treatment reviews.

[19]  M. Kawakami,et al.  Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine. , 2005, Cytokine.

[20]  E. Lakatta,et al.  Cardioprotection by Recombinant Human Erythropoietin Following Acute Experimental Myocardial Infarction: Dose Response and Therapeutic Window , 2005, Cardiovascular Drugs and Therapy.

[21]  J. Barton,et al.  Allele frequencies of hemojuvelin gene (HJV) I222N and G320V missense mutations in white and African American subjects from the general Alabama population , 2004, BMC Medical Genetics.

[22]  P. Ghezzi,et al.  Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Dirk Schrijvers,et al.  The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. , 2004, European journal of cancer.

[24]  S. E. Samuels,et al.  The role of ubiquitin-proteasome-dependent proteolysis in the remodelling of skeletal muscle. , 2004, The Proceedings of the Nutrition Society.

[25]  A. Cerami,et al.  Erythropoietin as a Tissue-Protective Cytokine in Brain Injury: What Do We Know and Where Do We Go? , 2004, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[26]  L. Harrison,et al.  Once‐weekly dosing of epoetin‐α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy , 2003, Cancer.

[27]  S. Anker,et al.  Cytokines, apoptosis and cachexia: the potential for TNF antagonism. , 2002, International journal of cardiology.

[28]  J. Madelmont,et al.  Chemotherapy inhibits skeletal muscle ubiquitin-proteasome-dependent proteolysis. , 2002, Cancer research.

[29]  M. McKenzie,et al.  Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Barrett-Lee,et al.  Improvement in quality of life for cancer patients treated with epoetin alfa. , 2001, European journal of cancer care.

[31]  A. Billiau,et al.  Cytokines and cachexia. , 1997, Nutrition.

[32]  L. Tessitore,et al.  Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. , 1993, The Journal of clinical investigation.

[33]  E. Aulbert.  [Anemia in malignant tumor diseases. II. Tumor-induced loss of transferrin as a cause of the development of anemia based on a rat model]. , 1989, Nuklearmedizin. Nuclear medicine.